Old and Newer methods for Bayesian updating

Slides:



Advertisements
Similar presentations
A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.
Advertisements

Hematopoietic stem cell transplantation
The BigWinPops and MM-USCPACK Programs, USC Laboratory of Applied Pharmacokinetics ( The BigWinPops and MM-USCPACK Programs, USC Laboratory.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
1 A Therapeutic Platelet Strategy Journal Club – Feb 21, 2007 Kristine Roland MD FRCPC TM Resident, UBC.
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
The USC Pmetrics and RightDose software The ONLY software with integrated pop modeling, simulation, and maximally precise dosage The ONLY software with.
Updated Results of a Phase I First-in-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic.
Locatelli F et al. Proc ASH 2013;Abstract 4378.
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.
G. Lucchini on behalf of the EBMT PDWP SCT in pediatric AML in 1CR: does the conditioning regimen matter? Scientific Day 12 th May, 2016 London.
(Donor T-Cells Transduced with iC9 Suicide Gene)
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
Treatment of Aplastic Anemia
Vose JM et al. Proc ASH 2011;Abstract 661.
Moskowitz CH et al. Proc ASH 2015;Abstract 182.
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1   CC-486 (Oral.
Palumbo A et al. Proc ASH 2012;Abstract 200.
Maury S et al. Proc ASH 2015;Abstract 1.
Stem Cell doubling is logarithmic
Retrospective analysis of conditioning regimen containing decitabine of allogeneic stem cell transplantation for myelodysplastic syndrome and myeloproliterative.
Korde N et al. Proc ASH 2012;Abstract 732.
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Supplemental table 1 Patients' characteristics Variables Number
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation
Shahad Abbas1,2 Alison H Thomson1,2 B) non-malignant patients.
Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT)
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Human Health and Disease
Multiple Model Dosage Design
Erba HP et al. Blood 2008;112: Abstract 558
Fowler NH et al. Proc ASCO 2010;Abstract 8036.
Rossi A et al. Proc ASCO 2011;Abstract 8008.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Clinical Pharmacokinetics
PREDICTIVE FACTORS AFFECTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION USING RIC REGIMENS: EXPERIENCE FROM A SINGLE CENTRE Dott.ssa M. Medeot.
Expert Perspectives on HSCT: Planning for Success
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Letermovir(Prevymis™) Guidelines for Inpatient Use
Grövdal M et al. Blood 2008;112:Abstract 223.
Forero-Torres A et al. Proc ASH 2011;Abstract 3711.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Zaja F et al. Proc ASH 2010;Abstract 966.
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
359 Pre-Transplant and Peri-d100 Gastrointestinal Dysbiosis Is Associated with the Subsequent Development of Chronic Graft-Versus-Host Disease Kate A Markey,
Yang Liu, Anne Chain, Rebecca Wrishko,
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Clinical Lymphoma, Myeloma and Leukemia
A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant.
Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.
Eliane Gluckman  Experimental Hematology 
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Frédéric Baron, Rainer Storb 
Kantarjian HM et al. Blood 2008;112:Abstract 635.
Assessing similarity of curves: An application in assessing similarity between pediatric and adult exposure-response curves July 31, 2019 Yodit Seifu,
Presentation transcript:

Old and Newer methods for Bayesian updating Roger Jelliffe, M.D. USC Lab of Applied Pharmacokinetics 11/14/2018 USC LAPK

Four types of Bayesian updating Maximum Aposteriori Probability (MAP). Multiple Model (MM) Bayesian updating. Hybrid Bayesian (MAP + MM) updating. Interacting Multiple Model (IMM) Bayesian updating 11/14/2018 USC LAPK

Maximum Aposteriori Probability (MAP). Can reach out toward an unusual patient But the MAP point misses the true patient Held back toward the prior Also, only 1 point. No graphic view of uncertainties. What to do? 11/14/2018 USC LAPK

11/14/2018 USC LAPK

2. Multiple Model (MM) Bayesian updating. Support points don’t change. Values of support points stay the same Use Bayes’ theorem to compute the Bayesian posterior probability of each support point, given patient’s data Problem: will not reach out beyond pop param ranges. May miss unusual patient. What to do? 11/14/2018 USC LAPK

Pop model has definite boundaries 11/14/2018 USC LAPK

3. Hybrid Bayesian posterior updating Start with MAP Bayesian. It reaches out, but not fully. Pop prior holds it back. Add new support points nearby, inside and outside, to precondition the pop model for the new patient data. Then do MM Bayesian on ALL the support points. We are implementing this now. Out soon. 11/14/2018 USC LAPK

Test Case Probabilities calculated on a 4x4 grid about optimal 5 percent increase/decrease between grid points 11/14/2018 USC LAPK

4. Bayesian for very unstable patients: interacting multiple model (IMM) Limitation of all current Bayesian methods: assume only 1 set of fixed parameters to fit the data. Sequential MAP or MM Bayesian same as fitting all at once. Relax this assumption. Let the “true patient” change during data analysis if more likely to do so. Hit evasive targets better. IMM. 11/14/2018 USC LAPK

11/14/2018 USC LAPK

What individualized therapy has done Digoxin Lidocaine Aminoglycosides Vancomycin Busulfan Methotrexate 11/14/2018 USC LAPK

What individualized therapy has done Digoxin 11/14/2018 USC LAPK

11/14/2018 USC LAPK

11/14/2018 USC LAPK

What individualized therapy has done Lidocaine 11/14/2018 USC LAPK

11/14/2018 USC LAPK

What individualized therapy has done Aminoglycosides 11/14/2018 USC LAPK

11/14/2018 USC LAPK

11/14/2018 USC LAPK

11/14/2018 USC LAPK

Vinks et al. Aminoglycoside therapy: 4 hospitals.(TDM 21:63-73, 1999) Adaptive TDM (ATM) vs ordinary TDM Patients 105 127 Inf on adm 48 62 Peak conc 10.6±2.9 ug/ml 7.6±2.2 p<0.01 Trough conc 0.7±0.6 1.4±1.3 p<.001 Mortality 9/105 18/127 p=.26 Mort, inf on adm 1/48 9/62 p=.023 11/14/2018 USC LAPK

Other aminoglycoside outcomes ATM TDM Nephrotoxicity 2.9% 13.4% p<.01 Hospital stay 20.0±1.4d 26.3±2.9 p=.045 Inf on adm 12.6±0.8d 18.0±1.4 p<.001 Cost (DFL) 13,125±9,267 16,882±17,721 p<.05 Inf on adm 8,883±3,778 11,743± 7,437 p<.001 11/14/2018 USC LAPK

What individualized therapy has done Vancomycin 11/14/2018 USC LAPK

11/14/2018 USC LAPK

Vanco IV Options 11/14/2018 USC LAPK

Vanco IV Options 11/14/2018 USC LAPK

What individualized therapy has done Busulfan 11/14/2018 USC LAPK

Bleyzac et al. Busulfan in 29 Ped BMT Pts Test Control PTS 29 29 VOD 3.4% 24.1%* Graft Failure 0.0% 12.0% Survival 82.8% 65.5% *p<.05 11/14/2018 USC LAPK

COST EFFECIVENESS STUDY OF CYCLOSPORIN BAYESIAN MONITORING IN PEDIATRIC BONE MARROW TRANSPLANTATION Nathalie BLEYZAC, Emmanuelle SAVIDAN, Claire GALAMBRUN Hôpital DEBROUSSE, Hospices Civils de Lyon 11/14/2018 USC LAPK

Context Bone marrow transplantation Numerous complications including graft versus host disease (GVHD) GVHD prophylaxis: Cyclosporine ± ATG 11/14/2018 USC LAPK

Bone marrow transplantation : Indications Malignant diseases : Leukemia (ALL, AML, CML, JMML), non Hodgkin lymphoma Myelodysplastic syndromes Non malignant diseases : Bone marrow failure, hemoglobinopathies Immunodeficiencies Metabolic disorders 11/14/2018 USC LAPK

Cyclosporine: PK/PD No dose-effect relationship Relationship between cyclosporine trough blood concentration and GVHD grades Existence of cyclosporine target blood concentrations specific to each type of graft and each pathology 11/14/2018 USC LAPK

Cyclosporine therapeutic monitoring : Empirical strategy YES NO  or  doses by 5 to 10% increment if trough blood concentration differ from target values (Cmin between 100 et 200ng/ml) new measure of trough blood concentration to verify it is within target values range More than one week is sometimes needed before finding the optimal dosage regimen 11/14/2018 USC LAPK

Cyclosporine therapeutic monitoring : MAP Bayesian monitoring strategy Home-made PK populations 3 dose control per week / 2 first weeks USCPACK: linear PK (≠ CsA) + “human neuronal network” 11/14/2018 USC LAPK

Methods (1) Strategies compared : Costs considered : Direct costs : Strategy A: Bayesian monitoring (Debrousse hospital’s) Strategy B: empirical monitoring (all other French centers) Costs considered : Direct costs : directly linked to GVHD treatment costs of monitoring strategies 11/14/2018 USC LAPK

Methods (2): Efficacy of cyclosporine Bayesian TDM Choice of efficacy endpoint : → Incidence of severe acute GVHD (grades III and IV ) → Relapses 11/14/2018 USC LAPK

Methods (3): Efficacy: data collection Strategy A : Data reported in a previous study: patients transplanted from Nov. 1999 to Oct. 2004 at Debrousse hospital 85 children 11/14/2018 USC LAPK

Methods (4): Efficacy: data collection Strategy B : Literature review : Medline request combining “bone marrow transplantation” AND “children” AND “GVHD” ; restriction on last 6 years → > 100 papers Selection of studies showing criterion previously defined 11/14/2018 USC LAPK

Methods (5): Efficacy: data collection Strategy B : Selection criterion Pediatric studies ≥ 15 patients Incidence of moderate and severe acute GVHD clearly indicated Exclusion criterion Rare pathologies Autologous graft Peripheral stem cell graft or umbilical cord blood graft if no data about BMT 11/14/2018 USC LAPK

Methods (6): Efficacy: data collection Strategy B : 9 studies Warning : cohorts differ from ours for different reasons Data synthesis Median percentages about moderate and severe acute GVHD incidence calculated from percentages reported in each study 11/14/2018 USC LAPK

Methods (7): Costs considered Cost saved by using strategy A Overcost generated by the treatment of one severe GVHD : Mean cost of treatment for a patient affected by severe GVHD – mean cost of treatment for a patient without GVHD or I-II Cost of carrying out strategy A 11/14/2018 USC LAPK

Methods (8) : Costs considered Cost of carrying out strategy A : Cyclosporine blood samples and dosages : Equivalent in both strategies Bayesian monitoring : Informatics material : insignificant Staff : 0.6 “équivalent temps plein” (ETP) of hospital pharmacist and 1.5 ETP of resident 11/14/2018 USC LAPK

Methods (9) : Costs considered Costs of treatment (severe acute GVHD / no GVHD) : Cost of hospitalization Cost of drugs used Cost of stable and labile blood products Parenteral nutrition Biological and imaging investigations Calculated from 10 patients’ files . 11/14/2018 USC LAPK

Results (1) : Strategy efficacy: incidence of GVHD Strategy A : Between 1999 and 2004 : Grade I-II : 48.2 % Grade III-IV : 8.2% Strategy B : Mean : Grade I-II : 39.4% Grade III-IV: 22.4% 11/14/2018 USC LAPK

Results (2) : Additional cost linked to severe GVHD Number of patients concerned : 26 BMT / year at Debrousse hospital of which 26 x 8.2% = 2.1 patients affected by severe acute GVHD each year. If cyclosporine was monitored according to classical strategy, it would be 26 × 22.4% = 5.8 patients affected by severe acute GVHD each year, i.e. 3.7 more. 11/14/2018 USC LAPK

Results (3) : Resources consumed (costs in euros) The additional cost for one severe acute GVHD is approximately 102 250 euros 11/14/2018 USC LAPK

Results (4) : Costs avoided by cyclosporine Bayesian monitoring Cost of severe GVHD saved (3.7 x 102250) : 378 325 euros Cost of carrying out strategy A : 111 000 euros Overall cost saved by using strategy A : 267 325 euros 11/14/2018 USC LAPK

Results (5): Sensitivity analysis Strategy A remains cost-effective when resources varies: Hospitalization cost : length of stay of 50 – 130 days Quantity of stable and labile blood products administered : 2000 to 72 000 euros Severe GVHD incidence variance above 12.5% 11/14/2018 USC LAPK

Conclusion Cyclosporin MAP Bayesian monitoring strategy is cost-effective as it allows : about 14% less severe acute GVHD about 270 000 euros of cost saving per year 11/14/2018 USC LAPK